{"filing":{"accession_number":"0001213900-26-097845","cik":"0001892500","ticker":"CMND","company_name":"Clearmind Medicine Inc.","form":"6-K","filing_date":"2026-09-08","report_date":"2026-09-08","primary_document":"ea0304830-6k_clearmind.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1892500/000121390026097845/ea0304830-6k_clearmind.htm"},"events":[{"id":31800,"run_id":29199,"accession_number":"0001213900-26-097845","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces Yale University IRB approval enabling patient recruitment for Parts B and C of Clearmind's Phase I/II CMND-100 clinical trial, following positive safety results from Part A. The disclosure is a material operational milestone for a clinical-stage biotech company—it represents regulatory clearance to advance a key clinical program at a leading academic medical center and directly enables acceleration of enrollment. While the event is clearly operational/clinical in nature, it does not fit the specific named categories (it is neither an earnings release, executive change, M\u0026A activity, nor a discrete financial event), making `operational_other` the appropriate classification.","company_name":"Clearmind Medicine Inc.","ticker":"CMND","filing_date":"2026-09-08","form":"6-K","submitted_at":null,"items":[{"id":34793,"accession_number":"0001213900-26-097845","item_number":"EX-99.1","item_title":"ea030483001ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces Yale University IRB approval enabling patient recruitment for Parts B and C of Clearmind's Phase I/II CMND-100 clinical trial, following positive safety results from Part A. The disclosure is a material operational milestone for a clinical-stage biotech company—it represents regulatory clearance to advance a key clinical program at a leading academic medical center and directly enables acceleration of enrollment. While the event is clearly operational/clinical in nature, it does not fit the specific named categories (it is neither an earnings release, executive change, M\u0026A activity, nor a discrete financial event), making `operational_other` the appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-08T11:44:38.279599+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34793,"accession_number":"0001213900-26-097845","item_number":"EX-99.1","item_title":"ea030483001ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces Yale University IRB approval enabling patient recruitment for Parts B and C of Clearmind's Phase I/II CMND-100 clinical trial, following positive safety results from Part A. The disclosure is a material operational milestone for a clinical-stage biotech company—it represents regulatory clearance to advance a key clinical program at a leading academic medical center and directly enables acceleration of enrollment. While the event is clearly operational/clinical in nature, it does not fit the specific named categories (it is neither an earnings release, executive change, M\u0026A activity, nor a discrete financial event), making `operational_other` the appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-08T11:44:38.279599+00:00","company_name":"Clearmind Medicine Inc.","ticker":"CMND","filing_date":"2026-09-08"}]}